CLINICA CODAFOR ANGELS & PRE-SEED INVESTORS
Built to reduce healthcare paperwork—starting with clinical coding in GP practices. Clinica Coda brings the letter, suggested codes and human review into one workspace.
Pre-pilot · Raising £250k
Independent validation. Practice pilots. A route to paid adoption.
01 / THE PROBLEM & THE WORKING PRODUCT
A diagnosis to record. A medicine change to check. A follow-up to notice. One letter creates several decisions.
Clinica Coda brings the source, code suggestions and human review together. The product is built; its impact in practice is the next test.
Source wording beside each suggestion.
Suspected, stopped and ruled out stay visible.
Accept, change or reject before reviewed export.
02 / THE EXPANSION THESIS
One letter. Several jobs. A focused first product with a wider ambition.
01 / THE FIRST MARKET
£58.1mUK annual coding-price ceiling · modelTurn correspondence into code suggestions, source evidence and a decision a person can review.
Pre-pilot. Assumes all UK registered patients at the proposed coding price.74.54m patients × 6.5p × 12 months.
Calculation & planning assumptions ↓
02 / THE NEXT WORKFLOWS
£120.8mUK annual full-offer ceiling · modelDocument routing. Referrals. Recalls. Follow-up. Explore more of the admin around the same letter.
Planned tools, not built. Includes coding; not an additional £120.8m. Future pricing unvalidated.74.54m patients × 13.5p × 12 months.
Calculation & planned modules ↓
03 / THE GLOBAL CATEGORY
$96.7bnglobal medical coding · 2033 analyst forecastHospital coding is a potential next chapter. It needs a separate product, standards and evidence.
Grand View Research: $48.2bn estimated in 2026. Includes in-house and outsourced work worldwide; not our reachable market.Source: Grand View Research.
Read the market estimate ↗
THE PRODUCT LOGIC
The ambition is to carry the source and its context through more of the workflow—without losing human control.
THE EXPANSION GATE
Independent checks. Measured pilots. Paying practices. Each new workflow follows evidence of demand and value.
Market ceilings and a global category forecast describe different scopes. They overlap and must not be added together. None is a revenue forecast or company valuation.
The film’s UK planning base is 74,539,737 registered patients across 7,695 practices. This combines country snapshots from different dates; the Welsh patient estimate was not independently confirmed. £58.1m = that planning base × £0.065 × 12. £120.8m = the same base × the planned £0.135 full-offer price × 12. The planned 13.5p price is 6.5p for coding plus two future modules at 3.5p each. Exact calculations use 74,539,737 patients; the cards round this base to 74.54m. Both assume 100% coverage before access, competition, adoption and costs. They are indicative price-based ceilings, not validated TAM or serviceable revenue.
Grand View Research’s public medical coding report estimates $43.8bn in 2025, $48.2bn in 2026 and forecasts $96.7bn in 2033, including in-house and outsourced activity. MarketsandMarkets uses a different scope and estimates $8.91bn in 2025, reaching $14.01bn in 2030. We show the broader category estimate with its scope and year; the estimates are not directly comparable. The full paid methodologies were not reviewed.
The global figure is context for a longer-term ambition, not Clinica Coda’s current addressable market. Hospital and international coding need additional classifications, integrations, assurance and commercial validation. No hospital revenue is included in the coding-only business scenario.
Proven adjacent tools could increase revenue per practice. A validated hospital product could open a different buyer base. The round starts with the first proof point.
NHS England identifies integration and automation opportunities across general-practice administration. UHL and UHN describe exploring AI across administration and clinical operations, including coding. These are category signals, not partnerships or endorsements of Clinica Coda.
Hospital coding uses ICD-10 and OPCS-4. The current GP SNOMED product cannot simply be relabelled. Later modules need their own demand, safety, data-protection and regulatory assessment. No valuation uplift is assumed.
THE CATEGORY IS MOVING
NHS England identifies integration and automation as routes to reducing practice administrative burden.
Read the NHS guidance ↗UHL and UHN describe AI work across administration and clinical operations, including clinical coding.
Read the trust announcement ↗Clinica Coda has a pre-pilot product. This round funds the evaluation and deployment work needed to test adoption.
See the next milestones ↓External examples show activity in the category. They are not Clinica Coda partnerships, endorsements or evidence of our results.
03 / EARLY EVIDENCE
SYNTHETIC DEVELOPMENT SET
106/10723 synthetic letters. Our answer key. Cases reused in tuning.
Run: 9 October 2026. Also found 153/153 expected facts and correctly labelled 130/132 assertions. One concept and two context labels were wrong; handling of expected uncoded items was 31/46. This is not overall clinical accuracy.
INDEPENDENTLY MARKED PUBLIC DE-IDENTIFIED LETTERS
141/14713 public real letters. Independently marked by a GMC-registered doctor-coder. Internal assessment, not clinical validation.
147 of 150 items marked on 12 October 2026 from a 3 October pipeline run. Three unmarked. Five wrong-code suggestions and one item that should not be filed remained. Missed facts were not measured.
Next: a second independent marker and a scoped 12-week practice pilot. Measure missed facts, review time, acceptance and cost to serve.
THE FIRST REVENUE MODEL / PROPOSED
per registered patient / month
£650 monthly for a 10,000-patient practice.Alternative: 15.99p per letter, software only. Target 3–5 pilots, then 10–25 paying practices if evidence supports progression. At the illustrative practice size, that is £78k–£195k annual recurring revenue: a scenario, not contracted revenue or a forecast.
Pricing, support costs and integration fees remain to be tested. No GP-admin or hospital revenue is included.
04 / WHY NOW · THE £250K PRE-SEED ROUND
A competitor has just raised $10m and still serves about 3% of practices. The race to prove it in practice is on, and it is early.
About 3%: 200+ GP surgeries (Healthcare Today, 14 Oct 2026) of 6,143 English practices (BMA, Aug 2026).The £250k pre-seed funds the three steps from built to proven: independent validation, the route to deployment, and a test of paid adoption.
Meet the founderEarly-stage, pre-pilot investment. Terms subject to agreement. SEIS status unconfirmed. Capital is at risk.
Online requests peak near 10 million a month and, since October 2025, must stay open all day. 74% of practices report more workload.
Sources: BMA; NHS England GP contract 2025/26The NHS 10 Year Health Plan backs AI to cut admin. A competitor has raised $10m, and three other established companies already sell AI coding.
Sources: NHS 10 Year Health Plan; Healthcare Today, 14 Oct 2026We found no published accuracy figures from the four established suppliers. The first independent pilot, safety case and integration route will set what buyers expect.
Source: our review of supplier pages, October 2026AI firms are buying UK clinical AI and GP software teams: Heidi bought AutoMedica and Doctolib bought Medicus, both this year. Examples, not a forecast or an offer.
Sources: Capital Brief, Feb 2026; Digital Health, May 2026Proposed £50k strategic first close, then £200k. The deck estimates about 12 months of lean runway. Lean first-year spend ~£177.1k. Planning assumptions, not supplier quotes.
Independent validation, live integration, clinical safety, security, data-protection arrangements and regulatory assessment remain to be established. EMIS agent simulation is not a live integration. Future modules need separate evaluation. Capital is at risk.
WHY THIS FOUNDER / WHY THIS PRODUCT
A coder who has led the queue—and built the software to help work through it.
Founder experience shapes the product. Independent pilots must prove the value.See it with the founder ↗Check the letter, quoted wording and suggested concept together.
Review negation, stopped medicines and concepts that add or lose meaning.
Accept, change or reject. Only accepted items enter reviewed exports.
This is the product approach, not a claim of unique capabilities or superiority over other suppliers. Quality, time savings and willingness to pay remain pilot questions.
FOUNDER / CLINICAL FIT
From the coding queue to the software.
Founder & CEO · MBBS · MSc Psychology of Mental Health
Lead Clinical Coder across seven GP sites. NHS coding experience. Built into the workflow.
Meet the founder ↗Built on years of experience leading clinical coding team across multiple GP Practices in North East London.
INVESTOR CONVERSATIONS
Request the current deck, ask about the funding plan, or arrange a walkthrough of the pre-pilot product.
Prefer email? invest@clinicacoda.com
Your details are emailed to the founder to respond to this enquiry. This website does not subscribe you to marketing or store a contact database. Please do not include patient information.
